Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 08:30 ET | Prometheus Biosciences
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
December 08, 2022 19:39 ET | Prometheus Biosciences
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
December 07, 2022 16:01 ET | Prometheus Biosciences
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
December 07, 2022 07:00 ET | Prometheus Biosciences
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all...
Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
November 09, 2022 16:01 ET | Prometheus Biosciences
- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position...
Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences to Participate at November Healthcare Conferences
November 01, 2022 08:00 ET | Prometheus Biosciences
SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
October 03, 2022 08:30 ET | Prometheus Biosciences
- PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF - - PRA052 is the second...
Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences to Participate at September Healthcare Conferences
August 31, 2022 16:00 ET | Prometheus Biosciences
SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
August 11, 2022 16:00 ET | Prometheus Biosciences
- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022 - - Bioavailability greater than 80% achieved upon completion of PRA023 subcutaneous bridging...
Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
July 18, 2022 16:00 ET | Prometheus Biosciences
- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 - -...